Myelodysplastic Syndromes – Epidemiology – Epidemiology Dashboard
Clarivate Epidemiology’s coverage of myelodysplastic syndromes (MDS) comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report both the diagnosed prevalence and the diagnosed incidence of MDS for each country, as well as annualized case counts projected to the national population.
Most patient populations are forecast over a period of 20 years for the mature markets and Europe, and 10 years for the other countries we cover.
All forecast data are available on Clarivate’s Insights Platform in tabular format, with options to download to MDS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.
Clarivate Epidemiology’s MDS forecast answers the following questions:
- How will changes in the levels of exposure to known risk or protective factors affect the number of people living with a diagnosis of MDS and the number of new diagnoses of MDS?
- In developing countries, what impact will economic growth and development have on the number of people living with a diagnosis of MDS and the number of new diagnoses of MDS?
- How will improvements in survival change the number of people living with a diagnosis of MDS?
- Of all people diagnosed with MDS, how many in each country across the major mature pharmaceutical markets are drug-treated?
- How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of MDS over the forecast period?
In addition to the total number of cases for each forecast year, Clarivate Epidemiology provides at least 10 years of forecast data for the following MDS subpopulations:
- Diagnosed MDS incident cases by histological subtypes
- Diagnosed MDS prevalent cases by histological subtypes
- Diagnosed incident cases by IPSS and IPSS- R
- Diagnosed prevalent cases by IPSS and IPSS- R
- FLT3 mutations
- Diagnosed incident cases by TP53 mutations.
- AML transformation events
- Drug-treated populations
Note: Coverage may vary by country.
